Xilio Therapeutics' Q3 collaboration revenue rises
I'm PortAI, I can summarize articles.
Xilio Therapeutics' Q3 collaboration revenue increased to $19.1 million from $2.3 million year-over-year. However, the net loss for Q3 widened to $16.3 million from $14.0 million. The company anticipates a cash runway into Q1 2027 and plans to submit an IND for XTX501 in mid-2026. R&D expenses rose to $14.3 million from $10.8 million. Analysts rate the stock as a 'strong buy' with a median 12-month price target of $2.00, 61.3% above its current price of $0.77.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments